Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4051-4056

  Ward, L M ^a,d   Denker, A E ^b   Porras, A ^b   Shugarts, S ^b   Kline, W ^b   Travers, R ^a   Mao, C ^b   Rauch, F ^a   Maes, A ^b   Larson, P ^b   Deutsch, P ^b   Glorieux, F H ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; COXALGIA; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; FEVER; HEADACHE; HEARTBURN; HUMAN; KNEE PAIN; LEG PAIN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MYALGIA; NAUSEA; OSTEOGENESIS IMPERFECTA; OUTCOMES RESEARCH; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; TABLET FORMULATION; TACHYCARDIA; VOMITING;

ADOLESCENT; ALENDRONATE; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; OSTEOGENESIS IMPERFECTA; TABLETS;

EID: 23044484929     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2054     Document Type: Article

References (26)

1. Porras AG, Holland SD, Gertz BJ 1999 Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315-328
2. Fleisch H 1998 Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
3. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA 1999 Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138
4. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ 1998 Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678
5. Kanis JA, Gertz BJ, Singer F, Ortolani S 1995 Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5:1-13
6. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs Jr RW, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
7. Khan SA, Vasikaran S, McCloskey EV, Beneton MN, Rogers S, Coulton L, Orgee J, Coombes G, Kanis JA 1997 Alendronate in the treatment of Paget's disease of bone. Bone 20:263-271
8. Rizzoli R, Buchs B, Bonjour JP 1992 Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer 50:706-712
9. Ward LM, Glorieux FH 2003 The spectrum of osteoporosis. In: Glorieux FH, Pettifor JM, Juppner H, eds. Pediatric bone: biology and diseases. 1st ed. New York: Academic Press; 401-442
10. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
11. Astrom E, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356-364
12. Zacharin M, Bateman J 2002 Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 15:163-174
13. Rauch F, Plotkin H, Zeitlin L, Glorieux FH 2003 Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610-614
14. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, Glorieux FH 2003 Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 111:e601-e603
15. Maasalu K, Haviko T, Martson A 2003 Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 92:452-455
16. Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116
17. Schwartz GJ, Brion LP, Spitzer A 1987 The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571-590
18. Kline WF, Matuszewski BK 1992 Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 583:183-193
19. Therapeutic Products Directorate 1997 ICH harmonized tripartite guidelines. Ottawa, Canada: Health Canada Publications
20. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG 1995 Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298
21. Lin JH, Duggan DE, Chen IW, Ellsworth RL 1991 Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932
22. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850
23. Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I, Thiebaud D 2000 Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 15:147-154
24. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G 2003 Fever after zoledronic acid administration is due to increase in TNF-α and IL-6. J Interferon Cytokine Res 23:649-654
25. Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299
26. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH 2003 Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986-992